AGP Executive Report
Last update: 11 hours agoMigraine Treatment: Eindhoven-based Salvia BioElectronics has implanted the first U.S. participant in a pivotal trial of its under-skin neuromodulation system for resistant migraine. The study aims to enroll about 150 adults across more than 20 sites. Heart Health: UMCG and Philips have launched a five-year, €27.6 million European research programme involving 22 studies and more than 14,000 patients, testing earlier, personalised cardiovascular care. Digital Privacy: The Consumentenbond is seeking changes to Meta’s AI camera glasses—or a sales ban in the Netherlands—over recordings that may expose sensitive information, including health data. A court hearing is set for November 26. Pregnancy Care: The Netherlands plans to end the 13-week ultrasound for pregnant women from 2028.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.